Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Lee, B S ^a   Kang, S ^a,b   Kim, K A ^c   Song, Y J ^c   Cheong, K H ^c   Cha, H Y ^a   Kim, C H ^a,b  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c SAMSUNG Electronics   (South Korea)

Author keywords

EGR 1; Invasion; Met; Migration; Nasopharyngeal carcinoma; SAIT301

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SAIT301; RECOMBINANT SCATTER FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; SAIT301; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE SILENCING; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE; WOUND HEALING;

ANTIBODIES, MONOCLONAL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WOUND HEALING;

EID: 84901011989     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.119     Document Type: Article

References (45)

1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-429.
2. Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 794-799.
3. Chou J, Lin YC, Kim J, You L, Xu Z, He B et al. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 2008; 30: 946-963.
4. Miller CL, Lee JH, Kieff E, Longnecker R. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994; 91: 772-776.
5. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005; 11: 8131-8144.
6. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327: 239-242.
7. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 1987; 84: 6379-6383.
8. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the Met protein. Nature 1989; 339: 155-156.
9. Gandino L, Di Renzo MF, Giordano S, Bussolino F, Comoglio PM. Protein kinase-c activation inhibits tyrosine phosphorylation of the Met protein. Oncogene 1990; 5: 721-725.
10. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene Met. Oncogene 1991; 6: 501-504.
11. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999; 31: 1357-1362.
12. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 863-867.
13. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 2001; 98: 7443-7448.
14. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998; 17: 3045-3054.
15. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 2001; 98: 10722-10727.
16. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21: 4885-4893.
17. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P et al. A selective small molecule inhibitor of Met kinase inhibits Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63: 7345-7355.
18. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y et al. Effect of Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends 2011; 5: 52-56.
19. Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001; 276: 14308-14314.
20. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM et al. In vivo targeting of SF/HGF and Met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002; 16: 108-110.
21. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
22. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001; 159: 27-33.
23. Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62: 589-596.
24. Zhou HY, Wan KF, Ip CK, Wong CK, Mak NK, Lo KW et al. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 2008; 582: 3415-3422.
25. Cheng JC, Chang HM, Leung PC. EGR-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene 2013; 32: 1041-1049.
26. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ et al. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene 2014; 33: 34-43.
27. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947-4953.
28. Lai JK, Wu HC, Shen YC, Hsieh HY, Yang SY, Chang CC. Kruppel-like factor 4 is involved in cell scattering induced by hepatocyte growth factor. J Cell Sci 2012; 125(Pt 20): 4853-4864.
29. Murai M, Shen X, Huang L, Carpenter WM, Lin CS, Silverman S et al. Overexpression of Met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int J Oncol 2004; 25: 831-840.
30. Yucel OT, Sungur A, Kaya S. Met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases. Otolaryngol Head Neck Surg 2004; 130: 698-703.
31. Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K et al. Expression of hepatocyte growth factor and Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006; 126: 88-94.
32. Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC et al. Overexpression of Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol 2012; 48: 1114-1119.
33. Oh YM, Song YJ, Lee SB, Jeong Y, Kim B, Kim GW et al. A new anti-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells 2012; 34: 523-529.
34. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H et al. MetMAb, the one-armed 5D5 anti-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-4368.
35. Li Y, Zhang S, Tang Z, Chen J, Kong W. Silencing of Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells. Tumour Biol 2011; 32: 1217-1224.
36. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG et al. Hepatocyte growth factor/ scatter factor differentially regulates expression of proangiogenic factors through EGR-1 in head and neck squamous cell carcinoma. Cancer Res 2005; 65: 7071-7080.
37. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor EGR- 1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003; 9: 1026-1032.
38. Kim CH, Lee JS, Kang SO, Bae JH, Hong SP, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol 2007; 43: 1021-1025.
39. Cheng JC, Klausen C, Leung PC. Hydrogen peroxide mediates EGF-induced downregulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol Endocrinol 2010; 24: 1569-1580.
40. Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelialmesenchymal transition. J Cell Biol 1997; 137: 1403-1419.
41. Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis 2012; 33: 1142-1148.
42. Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/EGR-1-mediated upregulation of Snail. EMBO J 2006; 25: 3534-3545.
43. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66: 10357-10364.
44. Lee BS, Cha HY, Shin YS, Kim YS, Kim CH. AY4, an agonistic anti-death receptor 4 MAB, induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation. Endocr Relat Cancer 2013; 20: 283-291.
45. Lee BS, Kang SU, Hwang HS, Kim YS, Sung ES, Shin YS et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett 2012; 322: 45-57.